Department of Neurology and Clinical Neurosciences, Cambridge Center for Brain Repair, University of Cambridge, Cambridge, United Kingdom.
J Clin Invest. 2013 Jun;123(6):2364-5. doi: 10.1172/JCI69690.
Translating new findings in the laboratory into therapies for patients is a slow and expensive process. The development of therapies for neurodegenerative diseases is further complicated by the difficulty in determining whether the drug truly retards the slow degenerative process or provides only symptomatic benefit. In this issue, Aviles-Olmos et al. describe a first in Parkinson's disease (PD) patient study using a drug previously approved for diabetes treatment. In addition to suggesting that the drug may indeed be disease modifying in PD, their innovative approach suggests there may be more rapid and inexpensive avenues for testing novel therapies in PD.
将实验室的新发现转化为患者的治疗方法是一个缓慢而昂贵的过程。神经退行性疾病治疗方法的发展进一步复杂化，因为很难确定药物是否真的延缓了缓慢的退行性过程，还是仅提供了症状上的益处。在本期中，Aviles-Olmos 等人描述了使用先前批准用于糖尿病治疗的药物对帕金森病 (PD) 患者进行的首次研究。除了表明该药物实际上可能对 PD 具有疾病修饰作用外，他们的创新方法还表明，在 PD 中测试新疗法可能有更快、更经济的途径。
